CDH2 and gastric cancer: Our results indicated that ICG-001 reversed the decrease of E-cadherin, and the increase of N-cadherin and vimentin in MKN45/R and NCI N87/R cells, manifesting that inhibition of β-catenin signaling by ICG-001 reverses EMT in trastuzumab-resistant gastric cancer cells.